Alyeska Investment Group’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Alyeska Investment Group’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,000	Closed	-$989K	–	824
2021 Q2	$989K	Hold	4,000	–	–	0.01%	586
2021 Q1	$975K	Buy	+4,000	New	+$982K	0.01%	596

Other funds holding EFTR

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Alyeska Investment Group's EFTR Position: Q3 2021 in Review

Alyeska Investment Group sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2021, closing a stake of 4,000 shares — an estimated $989K sold.

Alyeska Investment Group first reported a position in EFTR in Q1 2021 and held it in 2 quarters. The position peaked at $989K in Q2 2021. 12 funds tracked by Wall St. Rank hold EFTR as of Q3 2021.

Alyeska Investment Group reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Alyeska Investment Group sold 4,000 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $989K.
Alyeska Investment Group first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
Alyeska Investment Group's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $989K in Q2 2021.
12 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Alyeska Investment Group's 13F filing for Q3 2021, filed 15 Nov 2021.